WO2005123130A3 - Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor - Google Patents

Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor Download PDF

Info

Publication number
WO2005123130A3
WO2005123130A3 PCT/DK2005/000403 DK2005000403W WO2005123130A3 WO 2005123130 A3 WO2005123130 A3 WO 2005123130A3 DK 2005000403 W DK2005000403 W DK 2005000403W WO 2005123130 A3 WO2005123130 A3 WO 2005123130A3
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatic
combinations
lipoxygenase inhibitor
arthritic diseases
improved treatments
Prior art date
Application number
PCT/DK2005/000403
Other languages
French (fr)
Other versions
WO2005123130A2 (en
Inventor
Stephan Christgau
Christian Hansen
Henrik Nilsson
Original Assignee
Osteologix As
Stephan Christgau
Christian Hansen
Henrik Nilsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteologix As, Stephan Christgau, Christian Hansen, Henrik Nilsson filed Critical Osteologix As
Publication of WO2005123130A2 publication Critical patent/WO2005123130A2/en
Publication of WO2005123130A3 publication Critical patent/WO2005123130A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

Combination treatments, wherein a 5-LOX inhibitor are administered together with a bone or cartilage beneficial compound in order to obtain a therapeutically beneficial effect in the treatment and/or prophylaxis of osteoarthritis, rheumatoid arthritis, osteoporosis or pain, and pharmaceutical compositions comprising a combination of a 5-LOX inhibitor and a bone and cartilage beneficial compound.
PCT/DK2005/000403 2004-06-17 2005-06-17 Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor WO2005123130A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400948 2004-06-17
DKPA200400948 2004-06-17

Publications (2)

Publication Number Publication Date
WO2005123130A2 WO2005123130A2 (en) 2005-12-29
WO2005123130A3 true WO2005123130A3 (en) 2006-02-02

Family

ID=34969752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000403 WO2005123130A2 (en) 2004-06-17 2005-06-17 Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor

Country Status (1)

Country Link
WO (1) WO2005123130A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044451A1 (en) * 2004-10-19 2006-04-27 Eli Lilly And Company Treatment of osteoarthritis and dosing regimen for arzoxifene
EP1947942B1 (en) * 2005-08-18 2015-07-29 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
CN101229154B (en) * 2007-01-26 2010-05-12 鲁南制药集团股份有限公司 Medicine compounds for treating osteoporosis
FR2953139B1 (en) * 2009-11-27 2012-04-13 Servier Lab PHARMACEUTICAL COMPOSITION COMPRISING STRONTIUM SALT, VITAMIN D AND CYCLODEXTRIN
WO2011156518A2 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CN103221052A (en) 2010-09-16 2013-07-24 施摩达生物技术有限公司 Fulvestrant compositions and methods of use
NL2016848B1 (en) 2016-05-27 2017-12-04 Oudshoorn Berendina Use of a bisphophosphonate salt in a medicament for a naturally occurring disease/disorder in a mammal.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440809A1 (en) * 1989-08-18 1991-08-14 Toray Industries, Inc. Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
WO2002026239A1 (en) * 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
WO2003020267A1 (en) * 2001-08-30 2003-03-13 Merckle Gmbh Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
WO2003066048A2 (en) * 2002-02-08 2003-08-14 F. Hoffmann-La Roche Ag Use of 15-lipoxygenase inhibitors for treating and preventing bone loss
WO2003082188A2 (en) * 2002-03-27 2003-10-09 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
EP1400243A1 (en) * 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440809A1 (en) * 1989-08-18 1991-08-14 Toray Industries, Inc. Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
WO2002026239A1 (en) * 2000-09-26 2002-04-04 Temple University Of The Commonwealth System Of Higher Education Analgesic and glucosamine compositions
WO2003020267A1 (en) * 2001-08-30 2003-03-13 Merckle Gmbh Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degeneration
WO2003066048A2 (en) * 2002-02-08 2003-08-14 F. Hoffmann-La Roche Ag Use of 15-lipoxygenase inhibitors for treating and preventing bone loss
WO2003082188A2 (en) * 2002-03-27 2003-10-09 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
EP1400243A1 (en) * 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRADY H R ET AL: "Lipoxins: Putative braking signals in best defense, inflammation and hypersensitivity", CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION 1996 UNITED STATES, vol. 5, no. 1, 1996, pages 20 - 27, XP008051486, ISSN: 1062-4821 *
CHARLIER C ET AL: "Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 38, no. 7-8, July 2003 (2003-07-01), pages 645 - 659, XP004448316, ISSN: 0223-5234 *
VANDERHOEK J Y ET AL: "Endogenous hydroxyeicosatetraenoic acids stimulate the human polymorphonuclear leukocyte 15-lipoxygenase pathway", JOURNAL OF BIOLOGICAL CHEMISTRY 1985 UNITED STATES, vol. 260, no. 29, 1985, pages 15482 - 15487, XP008051490 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof

Also Published As

Publication number Publication date
WO2005123130A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2005123130A3 (en) Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL172773A0 (en) Formulations for the treatment of arhritis conditions
MXPA04001876A (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis.
WO2008024978A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
HK1134788A1 (en) Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
PT2054045E (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
RS20060662A (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
WO2008112773A3 (en) Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
NZ591496A (en) A medicinal comprising ibuprofen and paracetamol and treatment for arthritis
MY148277A (en) Treatment of cartilage disorders with fgf-18
MY149863A (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2005011721A3 (en) Use of a pak inhibitor for the treatment of a joint disease
MX2008011454A (en) Novel use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses.
WO2007044321A3 (en) Latent procytotoxins and uses thereof
WO2008024970A3 (en) Tetrahydroindolone and tetrahydroindazolone derivatives
WO2007059874A3 (en) Compositions for the treatment of osteoarthritis and to nourish the synovial fluid
WO2007031853A3 (en) Therapeutic combination of hamlet and a hdac inhibitor to treat cancer
GB0406912D0 (en) Pharmaceutical composition for prophylaxis or treatment of osteoporosis and method to prepare the same
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2003080568A3 (en) Probucol derivatives
WO2009041799A9 (en) Pharmaceutical composition combining diacerein and chondroitin sulphate and use thereof in the treatment of osteoarthritis and related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase